SMAD4 Antibody

Immunohistochemistry (FFPE): 1-2ug/ml for 30 min at RT

Optimal dilution of the SMAD4 antibody should be determined by the researcher.

Signaling from the ligand-activated membrane receptor serine/threonine kinases to nuclear targets is mediated by a set of evolutionarily conserved proteins known as DPC4. Upon ligand binding, the receptors of the TGF- family phosphorylate SMAD proteins (SMAD1 and SMAD2). These proteins then move into the nucleus, where they activate transcription. To carry out this function, the receptor activated SMAD1 and 2 require association with the product of deleted in pancreatic carcinoma, locus 4 (DPC4), also known as SMAD4. SMAD4/DPC4 is also implicated as a tumor suppressor, since it is inactivated in more than half of pancreatic carcinomas and to a lesser extent in a variety of other cancers. SMAD4 is absent in approximately 80% of pancreatic adenocarcinoma, but rarely in endometrial, colorectal, ovarian, lung, breast adenocarcinomas, and malignant melanom. SMAD4 is an important marker for confirming a diagnosis of pancreatic adenocarcinoma. Patients with pancreatic adenocarcinomas with SMAD4 protein expression had significantly longer survival than SMAD4 negative patients.

Purified

1 mg/ml in 1X PBS; BSA free, sodium azide free

Recombinant full-length human protein was used as the immunogen for the SMAD4 antibody.

This SMAD4 antibody is available for research use only.

Cytoplasmic & Nuclear

Protein G affinity chromatography

Q13485